HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

remogliflozin etabonate

orally administered hypoglycemic agent; structure in first source

Also Known As:

4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-beta-D-glucopyranoside

Networked: 16 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - remogliflozin etabonate: 16
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - remogliflozin etabonate: 16

Experts

1.	Hussey, Elizabeth K: 5 articles (07/2015 - 11/2012)
2.	Dobbins, Robert L: 4 articles (07/2015 - 11/2012)
3.	O'Connor-Semmes, Robin: 4 articles (07/2015 - 11/2012)
4.	Tao, Wenli: 4 articles (07/2015 - 03/2013)
5.	Kapur, Anita: 3 articles (07/2015 - 04/2013)
6.	O'Connor-Semmes, R: 3 articles (01/2015 - 01/2012)
7.	Mohan, Brij: 2 articles (04/2022 - 04/2020)
8.	Suryawanshi, Sachin: 2 articles (04/2022 - 04/2020)
9.	Aravind, S R: 2 articles (04/2020 - 01/2020)
10.	Cheatham, Bentley: 2 articles (09/2015 - 07/2015)

Related Diseases

1.	Insulin Resistance 10/01/2008 - "In high-fat diet-fed Goto-Kakizaki rats, remogliflozin etabonate improved hyperglycemia, hyperinsulinemia, hypertriglyceridemia, and insulin resistance. " 09/01/2015 - "Remogliflozin etabonate (Remo) is an inhibitor of the sodium glucose-dependent renal transporter 2 (SGLT2), and improves insulin sensitivity in type 2 diabetics. "
2.	Hyperglycemia 10/01/2008 - "In high-fat diet-fed Goto-Kakizaki rats, remogliflozin etabonate improved hyperglycemia, hyperinsulinemia, hypertriglyceridemia, and insulin resistance. " 07/01/2015 - "Remogliflozin etabonate (RE), the prodrug of remogliflozin, is an inhibitor of the sodium glucose-dependent renal transporter 2 (SGLT2), enabling urinary glucose excretion to reduce hyperglycemia for the treatment of type 2 diabetes. "
3.	Hypertriglyceridemia 10/01/2008 - "In high-fat diet-fed Goto-Kakizaki rats, remogliflozin etabonate improved hyperglycemia, hyperinsulinemia, hypertriglyceridemia, and insulin resistance. "
4.	Hyperinsulinism (Hyperinsulinemia) 10/01/2008 - "In high-fat diet-fed Goto-Kakizaki rats, remogliflozin etabonate improved hyperglycemia, hyperinsulinemia, hypertriglyceridemia, and insulin resistance. "
5.	Type 2 Diabetes Mellitus (MODY) 01/01/2015 - "Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes." 01/01/2015 - "Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes." 01/01/2020 - "Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy." 05/13/2013 - "First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus." 04/01/2020 - "Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial."

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Sodium
3.	Sodium-Glucose Transporter 2
4.	Vildagliptin
5.	Sodium-Glucose Transporter 2 Inhibitors
6.	Prodrugs
7.	Symporters
8.	Metformin (Glucophage)
9.	Blood Glucose (Blood Sugar)

Related Therapies and Procedures

1.	Therapeutics